Redefine What’s Possible: A Potential New Treatment Paradigm for Patients with Ischemic Disorders

DiaMedica Therapeutics is committed to improving the lives of individuals battling serious vascular diseases by developing innovative therapies that reduce ischemia. With an initial focus on preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), we are dedicated to advancing patient care through a novel approach that centers around reversing the effects of the ischemic injury to improve patient outcomes.

Our Focus

Featured Event

DiaMedica’s Interim Phase 2 (Part 1a) Preeclampsia Results

July 17, 2025 | 4:30 pm EDT

Click this link to listen to the replay

Click this link to view the presentation

Click here to read the call script

Click here to read the press release

Preeclampsia and Fetal Growth Restriction

Preeclampsia (PE) is a potentially life-threatening disorder that occurs when the placenta fails to adhere properly causing elevated blood pressure and other organ damage and is one of the leading causes of maternal mortality worldwide. There are currently no approved treatment options to address the underlying disease, and short-term symptom management is the only available option for patients.

Fetal growth restriction (FGR) is another pregnancy complication that can often occur in patients with or without preeclampsia due to reduced blood flow to the placenta. It is a condition where the fetus is not growing as expected, often leading to premature birth, low birth weight, stillbirth, or potential long-term health complications. There are currently no approved treatment options for FGR.

Acute Ischemic Stroke

Acute ischemic stroke (AIS) occurs when a blood clot blocks a vessel supplying blood to the brain, leading to a sudden loss of oxygen and nutrients, and, if not corrected, ultimately neuronal cell death. More than 7.5 million acute ischemic strokes occur worldwide each year and no new treatments have been approved in over 25 years. Currently approved therapies are only available to approximately 20% of AIS patients as they are limited by treatment window and availability of specialized care.

DM199: A Novel, Safe Solution for Ischemic Disorders

DiaMedica’s lead drug candidate, DM199, is a recombinant form of a naturally occurring protein called human tissue kallikrein-1 (rhKLK1). It acts through a novel mechanism of action to restore vascular health and function, with the potential to modify disease progression in preeclampsia and fetal growth restriction and enhance collateral blood flow in patients with acute ischemic stroke.

View Our Pipeline

Stock Information